SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 9.95M shares outstanding
USSCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Ann F. Hanham, Ph.D.
Director
Armando Anido
Director
David Angulo, M.D.
Chief Executive Officer, President and Director
David Hastings
Director
Employees
18
Country
US
Sector
Healthcare
Website
scynexis.com
Loading congressional disclosures…
based on 9.95M shares outstanding
US30d Avg
557.10K
60d Avg
308.10K
90d Avg
283.12K
